Chinese Vaccine Developers' Latest COVID Shots Target XBB Subvariants

Chinese vaccine companies WestVac, Sinocelltech and Walvax/RNACure are leading domestic efforts to develop new shots targeting emerging SARS-CoV-2 subvariants.

COVID XBB — The Omicron XBB.1.5 sublineage had become the most prevalent COVID-19 strain in China by mid-year • Source: Shutterstock

Chinese makers of COVID-19 vaccines are shifting their development focus to multi-valent shots that target the Omicron XBB.1.5 sublineage, which had become the most prevalent in China by mid-year.

Chengdu-based WestVac Biopharma and its partner West China Medical Center of Sichuan University plan to investigate WSK-V101C in a Phase...